ACPT-1 | CAS#194918-76-8 | mGlu receptor agonist

MedKoo Cat#: 563216 | Name: ACPT-1

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ACPT-1 is a blood-brain barrier permeable agonist of group III metabotropic glutamate (mGlu) receptors. In primary neuronal cell cultures ACPT-I (1-200 μM), applied 30 min-3 h after starting the exposure to KA (150 μM), significantly attenuated the KA-induced LDH release, increased cell viability, and inhibited caspase-3 activity both in cortical and hippocampal cell cultures.

Chemical Structure

ACPT-1

CAS#194918-76-8

Theoretical Analysis

MedKoo Cat#: 563216

Name: ACPT-1

CAS#: 194918-76-8

Chemical Formula: C8H11NO6

Exact Mass: 217.0586

Molecular Weight: 217.17

Elemental Analysis: C, 44.24; H, 5.11; N, 6.45; O, 44.20

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
10mg	USD 630.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ACPT-1; ACPT 1; ACPT1;

IUPAC/Chemical Name

(1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid

InChi Key

FERIKTBTNCSGJS-KIGHRTHISA-N

InChi Code

InChI=1S/C8H11NO6/c9-8(7(14)15)1-3(5(10)11)4(2-8)6(12)13/h3-4H,1-2,9H2,(H,10,11)(H,12,13)(H,14,15)/t3-,4+,8-

SMILES Code

O=C([C@@]1(N)C[C@@H](C(O)=O)[C@@H](C(O)=O)C1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 217.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jantas D, Gręda A, Gołda S, Korostyński M, Lasoń W. The neuroprotective effects of orthosteric agonists of group II and III mGluRs in primary neuronal cell cultures are dependent on developmental stage. Neuropharmacology. 2016 Dec;111:195-211. doi: 10.1016/j.neuropharm.2016.09.003. Epub 2016 Sep 4. PubMed PMID: 27600687. 2: Domin H, Gołembiowska K, Jantas D, Kamińska K, Zięba B, Smiałowska M. Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivo. Neurotox Res. 2014 Jul;26(1):99-113. doi: 10.1007/s12640-013-9455-7. Epub 2014 Jan 9. PubMed PMID: 24402869; PubMed Central PMCID: PMC4035549. 3: Konieczny J, Lenda T. Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082. Pharmacol Rep. 2013;65(5):1194-203. PubMed PMID: 24399715. 4: Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis. 2014 Jan;61:55-71. doi: 10.1016/j.nbd.2013.09.013. Epub 2013 Sep 27. Review. PubMed PMID: 24076101; PubMed Central PMCID: PMC3875303. 5: Pałucha-Poniewiera A, Novák K, Pilc A. Group III mGlu receptor agonist, ACPT-I, attenuates morphine-withdrawal symptoms after peripheral administration in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1454-7. doi: 10.1016/j.pnpbp.2009.07.029. Epub 2009 Aug 4. PubMed PMID: 19660510. 6: Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology. 2008 Sep;55(4):483-90. doi: 10.1016/j.neuropharm.2008.06.038. Epub 2008 Jun 27. PubMed PMID: 18625257. 7: Pałucha-Poniewiera A, Kłodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S, Frauli M, Neuville P, Pilc A. Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology. 2008 Sep;55(4):517-24. doi: 10.1016/j.neuropharm.2008.06.033. Epub 2008 Jun 27. PubMed PMID: 18619473. 8: Wierońska JM, Kłak K, Pałucha A, Brański P, Pilc A. Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res. 2007 Dec 12;1184:88-95. Epub 2007 Oct 13. PubMed PMID: 17976546. 9: Gelmi ML, Caputo F, Clerici F, Pellegrino S, Giannaccini G, Betti L, Fabbrini L, Schmid L, Palego L, Lucacchini A. 1-Aminocyclopentane-1,2,4-tricarboxylic acids screening on glutamatergic and serotonergic systems. Bioorg Med Chem. 2007 Dec 15;15(24):7581-9. Epub 2007 Sep 12. PubMed PMID: 17900912. 10: Konieczny J, Wardas J, Kuter K, Pilc A, Ossowska K. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience. 2007 Mar 16;145(2):611-20. Epub 2007 Jan 16. PubMed PMID: 17224239. 11: Stachowicz K, Chojnacka-Wójcik E, Kłak K, Pilc A. Anxiolytic-like effects of group III mGlu receptor ligands in the hippocampus involve GABAA signaling. Pharmacol Rep. 2006 Nov-Dec;58(6):820-6. PubMed PMID: 17220539. 12: Stachowicz K, Chojnacka-Wójcik E, Kłak K, Pilc A. Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology. 2007 Feb;52(2):306-12. Epub 2006 Oct 3. PubMed PMID: 17020774. 13: Kłak K, Pałucha A, Brański P, Sowa M, Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressant-like effects in rats. Amino Acids. 2007 Feb;32(2):169-72. Epub 2006 Aug 2. PubMed PMID: 16868652. 14: Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S, Pilc A. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids. 2007 Feb;32(2):179-88. Epub 2006 May 15. Review. PubMed PMID: 16699817. 15: Wierońska JM, Szewczyk B, Pałucha A, Brański P, Zieba B, Smiałowska M. Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacol Rep. 2005 Nov-Dec;57(6):734-43. PubMed PMID: 16382191. 16: Panatier A, Poulain DA, Oliet SH. Regulation of transmitter release by high-affinity group III mGluRs in the supraoptic nucleus of the rat hypothalamus. Neuropharmacology. 2004 Sep;47(3):333-41. PubMed PMID: 15275822. 17: Uehara S, Muroyama A, Echigo N, Morimoto R, Otsuka M, Yatsushiro S, Moriyama Y. Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans. Diabetes. 2004 Apr;53(4):998-1006. PubMed PMID: 15047615. 18: Pałucha A, Tatarczyńska E, Brański P, Szewczyk B, Wierońska JM, Kłak K, Chojnacka-Wójcik E, Nowak G, Pilc A. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology. 2004 Feb;46(2):151-9. PubMed PMID: 14680755. 19: Xi ZX, Shen H, Baker DA, Kalivas PW. Inhibition of non-vesicular glutamate release by group III metabotropic glutamate receptors in the nucleus accumbens. J Neurochem. 2003 Dec;87(5):1204-12. PubMed PMID: 14622100. 20: Moldrich RX, Chapman AG, De Sarro G, Meldrum BS. Glutamate metabotropic receptors as targets for drug therapy in epilepsy. Eur J Pharmacol. 2003 Aug 22;476(1-2):3-16. Review. PubMed PMID: 12969743.